Podcasts about copd

How would you manage this patient whose chronic obstructive pulmonary disease (COPD) symptoms are not well controlled? Credit available for this activity expires: 10/30/26 Earn Credit / Learning Objectives & Disclosures:  https://www.medscape.org/viewarticle/breathing-new-life-copd-empowering-patients-through-therapy-2025a1000teq?ecd=bdc_podcast_libsyn_mscpedu  

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview Dr. Andrew Lee, Vice President, Clinical Research at Uniquity Bio, about Thymic Stromal Lymphopoietin (TSLP) and eosinophilic esophagitis (EOE). Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:49] Co-host Ryan Piansky introduces the episode, brought to you thanks to the support of Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:13] Holly introduces today's topic, Thymic Stromal Lymphopoietin (TSLP) and eosinophilic esophagitis (EOE), and today's guest, Dr. Andrew Lee, Vice President, Clinical Research at Uniquity Bio.   [1:36] Dr. Lee has nearly 20 years of experience in the clinical development of new vaccines, biologics, and drugs. Holly welcomes Dr. Lee.   [1:52] Dr. Lee trained in internal medicine and infectious diseases.   [1:58] Dr. Lee has been fascinated by the immune system and how it can protect people against infections, what happens when immunity is damaged, as in HIV and AIDS, and how to apply that knowledge to boost immunity with vaccines to prevent infections.   [2:16] Dr. Lee led the clinical development for a pediatric combination vaccine for infants and toddlers. It is approved in the U.S. and the EU.   [2:29] Dr. Lee led the Phase 3 Program for a monoclonal antibody to prevent RSV, a serious infection in infants. That antibody was approved in June 2025 for use in the U.S.   [2:44] In his current company, Dr. Lee leads research into approaches to counteract an overactive immune system. They're looking at anti-inflammatory approaches to diseases like asthma, EoE, and COPD.   [2:58] Dr. Lee directs the ongoing Phase 2 studies that they are running in those areas.   [3:28] Dr. Lee sees drug development as a chance to apply cutting-edge research to benefit people. He trained at Bellevue Hospital in New York City in the 1990s.   [3:40] When Dr. Lee started as an intern, there were dedicated ICU wards for AIDS patients because many of the sickest patients were dying of AIDS and its complications.    [3:52] Before the end of Dr. Lee's residency, they shut down those wards because the patients were on anti-retroviral medications and were doing so well that they were treated as outpatients. They didn't need dedicated ICUs for AIDS patients anymore.   [4:09] For Dr. Lee, that was a powerful example of how pharmaceutical research and drug regimen can impact patients' lives for the better by following the science. That's what drove Dr. Lee to go in the direction of research.   [4:48] Dr. Lee explains Thymic Stromal Lymphopoietin (TSLP). TSLP serves as an alarm signal for Type 2 or TH2 inflammation, a branch of the immune responses responsible for allergic responses and also immunity against parasites.   [5:17] When the cells that line the GI tract and the cells that line the airways in our lungs receive an insult or an injury, they get a danger signal, then they make TSLP.   [5:28] This signal activates other immune cells, like eosinophils and dendritic cells, which make other inflammatory signals or cytokines like IL-4, IL-13, and IL-5.   [5:47] That cascade leads to inflammation, which is designed to protect the body in response to the danger signal, but in some diseases, when there's continued exposure to allergens or irritants, that inflammation goes from being protective to being harmful.   [6:15] That continued inflammation, over the years, can lead to things like the thickened esophagus with EoE, or lungs that are less pliant and less able to expand, in respiratory diseases.   [6:48] Dr. Lee says he thinks of TSLP as being a master switch for this branch of immune responses. If you turn on TSLP, that turns on a lot of steps that lead to generating an allergic type of response.   [7:06] It's also the same type of immune response that can fight off parasite infections. It's the first step in a cascade of other steps generating that type of immune response.   [7:30] Dr. Lee says people have natural genetic variation in the genes that incur TSLP.   [7:38] Observational studies have found that some people with genetic variations that lead to higher levels of TSLP in their bodies had an increased risk for allergic inflammatory diseases like EoE, atopic dermatitis, and asthma.   [8:13] Studies like the one just mentioned point to TSLP being important for increased risk of developing atopic types of diseases like EoE and others. There's been some work done in the laboratory that shows that TSLP is important for activating eosinophils.    [8:38] There's accumulating evidence that TSLP activation leads to eosinophil activation, other immune cells, or white blood cells getting activated.   [9:07] Like a cascade, those cells turn on T-cells and B-cells, which are like vector cells. They lead to direct responses to fight off infections, in case that's the signal that leads to the turning on TSLP.   [9:48] Ryan refers to a paper published in the American Journal of Gastroenterology exploring the role of TSLP in an experimental mouse model of eosinophilic esophagitis. Ryan asks what the researchers were aiming to find.   [10:00] Dr. Lee says the researchers were looking at the genetic studies we talked about, the observational studies that are beginning to link more TSLP with more risk for EoE and those types of diseases.   [10:12] The other type of evidence that's accumulating is from in vitro (in glass) experiments or test tube experiments, where you take a couple of cells that you think are relevant to what's going on.   [10:28] For example, you could get some esophageal cells and a couple of immune cells, and put TSLP into the mix, and you see that TSLP leads to activation of those immune cells and that leads to some effects on the esophageal cells.   [10:42] Those are nice studies, but they're very simplified compared to what you can do in the body. These researchers were interested in extending those initial observations from other studies, but working in the more realistic situation of a mouse model.   [11:00] You have the whole body of the mouse being involved. You can explore what TSLP is doing and model a disease that closely mimics what's happening with EoE in humans.   [12:23] They recreated the situation of what seems to be happening in EoE in people. We haven't identified it specifically, but there's some sort of food allergen in patients with EoE that the immune system is set off by.   [12:55] What researchers are observing in this paper is that in these mice that were treated with oxazolone, there is inflammation in the esophagus, an increase in TSLP levels, and eosinophils going into the esophageal tissues.   [13:15] Dr. Lee says, that's one of the main ways we diagnose EoE; we take a biopsy of the esophagus and count how many eosinophils there are. Researchers saw similar findings. The eosinophil count in the esophageal tissues went way up in these mice.    [13:34] Researchers also saw other findings in these mice that are very similar to EoE in humans, such as the esophageal cells lining the esophagus proliferating. They even saw that new blood vessels were being created in that tissue that's getting inflamed.   [14:00] Dr. Lee thinks it's a very nice paper because it shows that correlation: Increase TSLP and you see these eosinophils going to the esophagus, and these changes that are very reminiscent of what we see in people with EoE.   [14:51] In this paper, the mice made the TSLP, and researchers were able to measure the TSLP in the esophageal tissue. The researchers didn't introduce TSLP into the mice. The mice made the TSLP in response to being repeatedly exposed to oxazolone.   [15:20] That's key to the importance of the laboratory work. The fact that the TSLP is made by the mice is important. It makes it a very realistic model for what we're seeing in people.   [15:41] In science, we like to see correlation. The researchers showed a nice correlation.   [15:46] When TSLP went up in these mice, and the mice were making more TSLP on their own, at the same time, they saw all these changes in the esophagus that look a lot like what EoE looks like in people.    [16:01] They saw the eosinophils coming into the esophagus. They saw the inflammation go up in the esophagus. What Dr. Lee liked about this paper is that they continued the story.   [16:15] The researchers took something that decreases TSLP levels, an antibody that binds to and blocks TSLP, and when they did that, they saw the TSLP levels come down to half the peak level.   [16:35] Then they saw improvement in the inflammation in the esophagus. They saw that the amount of eosinophils decreased, and the multiplication of the esophageal cells went down. The number of new blood vessels went down after the TSLP was reduced.   [16:53] Dr. Lee says, you see correlation. The second part is evidence for causation. When you take TSLP away, things get better. That gives us a lot of confidence that this is a real finding. It's not just observational. There is causation evidence here.   [18:26] Ryan asks if cutting TSLP also help reduce other immune response cells. Dr. Lee says TSLP is the master regulator for this Type 2 inflammation. It definitely touches and influences other cells besides eosinophils.   [18:44] TSLP affects dendritic cells, which are an important type of immune cell, like a coordinating cell that instructs other cells within the immune system what to do. In this paper, they looked at a lot of other effects of TSLP on the tissues of the body.   [19:10] Dr. Lee says, There's a lot of research on TSLP, and one of the reasons we're excited about the promise of TSLP is that it's so far upstream; so much of the beginning, that it's affecting other cells.   [19:29] Its effects could be quite broad. If we're able to successfully block TSLP, we could block a lot of different effects.   [19:40] One treatment for EoE is dupilumab, which blocks IL-4 and IL-13 specifically, and that works well, but TSLP has the potential to have an even greater effect than blocking IL-4 and IL-13, since it is one step before turning on IL-4 and IL-13.    [20:14] That's one of the reasons researchers are excited about the promise of blocking TSLP. There are studies ongoing of TSLP blockers in people with EoE.   [20:34] Ryan asks if there are negative repercussions from blocking TSLP. Dr. Lee says in this study and in people, we are not completely blocking TSLP by any means. There will still be residual TSLP activated, even with very potent drugs.   [21:01] In the study, they block TSLP about 50%‒60%. TSLP is involved in immunity against parasites. In studies with people, they make sure not to include anybody who has an active parasitic infection. A person under treatment should not be in a study.   [21:27] Dr. Lee says we haven't seen any problems with parasitic infections becoming more severe, but that is a theoretical possibility, so for that reason, in studies with TSLP blockers, we generally exclude patients with known parasitic infections.   [22:17] What excited Dr. Lee in this paper was that they showed that when you block TSLP in the mice, then you get real effects in their tissues. Eosinophils went away. The thickening of the basal layers in the esophagus got much better.   [22:38] That kind of real effect reflected in the tissue is super exciting to see. That gives us more confidence that this could work in people, since we're seeing it in a realistic whole-body model in the mice.   [23:12] Dr. Lee says there are ongoing clinical studies on TSLP blockers for EoE. His company is studying an antibody that blocks TSLP in eczema, COPD, and EoE. One of the exciting things about immunology is that it affects many different parts of the body.   [23:42] EoE is associated with other immune-type disorders. There's a high percentage of patients with EoE who have other diseases. EoE coexists with asthma, atopic dermatitis, and chronic rhinitis.   [24:09] It's exciting that if you figure out something that's promising for one disease that TSLP affects, it could have very broad-ranging implications for a variety of diseases.   [24:22] Ryan shares his experience of his doctor talking to him about a TSLP blocker, tezepelumab, as a potential option when it's out of clinical trials. It would target something a little higher up the chain and help with some of his remaining symptoms.   [24:59] Ryan is excited to hear that this research is so encouraging and how it could potentially help treat EoE, asthma, and other conditions, all at once.   [25:16] Dr. Lee says that being in these later-stage studies is super exciting. If these late-stage trials are successful, the next step is to apply for regulatory approval with the various agencies around the world.   [26:40] Dr. Lee shares one takeaway for listeners to remember. Think of TSLP as an alarm that turns on inflammation. He compares TSLP to turning on an alarm during a robbery. There are multiple steps designed to protect the bank and the money.   [27:20] To extend that analogy, with TSLP, once you turn it on, all these other steps are going to happen. Inflammation is designed to protect the body. It's a protective response. If there's an infection, it can clear the infection.   [27:38] If the infection persists, as in HIV, the immune response, which is protective and beneficial, eventually becomes damaging. It becomes dysfunctional. In EoE, if you continually eat the allergic food, the inflammation becomes damaging to the esophagus.   [28:27] Long-term inflammation leads to replacing the normal esophageal tissue with fibrotic tissue, and that's why the esophagus eventually gets hardened and less able to let the food go through.   [28:40] In respiratory diseases, the soft tissue of the lung gets replaced with thicker tissue, and the lung is not able to expand.   [28:54] Dr. Lee says he people to think about TSLP as this master alarm switch. We hope that if you could turn off that TSLP, you could then avoid a lot of the complications that we see with chronic inflammation in these conditions.   [29:14] We're hopeful that you could even take away the symptoms that you see in these diseases, make patients feel better, and with extended treatment, you could begin to reverse some of the damage resulting from inflammation.   [29:32] Ryan likes that analogy and how Dr. Lee has concisely explained these complicated concepts.   [29:51] Dr. Lee thanks Holly and Ryan and adds one more plea to listeners. Please consider getting involved with research. Clinical trials cannot be done without patients. We need patients to advance new treatments.   [30:27] Researchers like Dr. Lee spend a lot of time thinking about how to make the studies not only informative but also fair to patients who decide to become involved. It's a lot of work and a fair amount of time commitment.   [30:44] If you don't want to be in a study, you can help by being on a patient feedback panel and reviewing protocols and informed consents. Follow your interests. Think about getting involved with research, however you can.   [31:06] Ryan and Holly are very grateful for the community, with so many wonderful clinicians and researchers, and so many patients who are willing to volunteer their time and their data to help researchers find better solutions going forward.   [31:26] Ryan thanks Dr. Lee for coming on and putting out that call to action. It's a great reminder for listeners and the patients in the community to look for those opportunities. Chat with your physician. Go to APFED's website. There's a link to active clinical trials.   [31:47] For our listeners who want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes below.   [31:53] For those looking to find specialists who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder at apfed.org/specialist.   [32:01] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.   [32:11] Ryan thanks Dr. Andrew Lee for joining us today. We learned a lot. Holly also thanks APFED's Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode: Andrew Lee, M.D., VP Clinical Research, Uniquity Bio   "A Mouse Model for Eosinophilic Esophagitis (EoE)" Current Protocols, Wiley Online Library   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   "I see drug development as a chance to apply cutting-edge research to benefit people." — Andrew Lee, M.D.   "When the cells that line the GI tract and the cells that line the airways in our lungs receive an insult or an injury, they get a danger signal, then they make TSLP." — Andrew Lee, M.D.   "Observational studies have found that some people with genetic variations that lead to higher levels of TSLP in their bodies had an increased risk for allergic inflammatory diseases like EoE, atopic dermatitis, and asthma." — Andrew Lee, M.D.   "There's a lot of research on TSLP, and one of the reasons we're excited about the promise of TSLP is that it's so far upstream; so much of the beginning, that it's affecting other cells." — Andrew Lee, M.D.   "Please consider getting involved with research. We can't do these clinical trials without patients. We need patients to advance new treatments for patients." — Andrew Lee, M.D.

 Chronic Obstructive Pulmonary Disease (COPD) is a group of lung diseases that cause airflow obstruction and other respiratory problems. There are various options for treating COPD, including the highly effective controller medication that helps improve a patient's lung function in the long-term. But as Antonio R. Anzueto, MD, professor of pulmonary and critical care at the University of Texas Health, San Antonio, explains, it is not easy for patients to use these medications. Listen as Dr. Anzueto and host Amy Attaway, MD, Cleveland Clinic, discuss the effectiveness of different COPD treatments, how COPD can affect other organs, and how AI might play into diagnosing COPD as technology advances. Support for this podcast is brought to you by Viatris and Theravance BioPharma. 

„20.000 Atemzüge, 20.000 Liter Luft – jeden Tag. Die Lunge ist ein Wunderwerk, das wir oft unterschätzen.“ – Heinz-Wilhelm Esser, vielen bekannt als Doc Esser, ist Kardiologe, Pneumologe, Bestsellerautor und einer der gefragtesten TV-Ärzte Deutschlands. In seiner täglichen Arbeit widmet er sich einem Organ, das uns täglich am Leben hält – und das doch erst Beachtung findet, wenn es Probleme macht. In dieser Folge BUNTE VIP GLOSS spricht Podcast-Host Jennifer Knäble mit Doc Esser über die unterschätzte Bedeutung der Lunge und darüber, wie wir sie langfristig gesund halten können. Denn über 14 Millionen Deutsche leiden an chronischen Atemwegserkrankungen – viele davon wären vermeidbar. Feinstaub, Viren, Pollen, Rauchen und Vaping setzen der Lunge massiv zu. Besonders gefährlich: E-Zigaretten, die oft als harmlos gelten, aber das Herz-Kreislauf-System und die Lunge ebenso belasten wie klassische Glimmstängel. Doc Esser erklärt, warum richtige Atmung, Bewegung und eine anti-entzündliche Ernährung der Schlüssel zu gesunden Atemwegen sind. Radfahren, Laufen, Schwimmen – alles, was die Atemmuskulatur stärkt, verbessert auch die Sauerstoffversorgung und schützt das Immunsystem. Und der Experte räumt mit Mythen auf: Hühnersuppe als Unterstützung des Immunsystems bei Atemwegserkrankungen? Ja, hilft wirklich. Kamillendampfbäder? Bitte nicht. Und er betont, wie wichtig Impfungen – etwa gegen Grippe – gerade für ältere Menschen und Lungenpatienten sind. Seine stärksten Aussagen: „Die Lunge ist ein wunderschönes Organ, das wir oft erst dann schätzen, wenn es zu spät ist.“ „Wir haben das richtige Atmen verlernt; dabei kann es so viel Druck wegnehmen.“ „Es ist ein Drama, dass wir unsere Lunge durch Umweltverschmutzung und Rauchen selbst schädigen.“ „Wir müssen die Lunge schützen und alles tun, damit sie bis ins hohe Alter ihrer Arbeit nachkommt.“ „Die richtige Atmung aktiviert unseren ‚Chillnerv‘ und hilft, Stress abzubauen.“ Seine klare Botschaft: Wer auf seine Lunge achtet, schützt nicht nur seine Gesundheit, sondern auch sein Lebensgefühl. Heinz-Wilhelm Esser alias Doc Esser bei BUNTE VIP GLOSS. Hier findet ihr alle Informationen zu unseren Podcast-Partnern: https://www.wonderlink.de/@buntevipgloss-partner Ein BUNTE Original Podcast.

Hoe meet jij de bloeddruk? De juiste armpositie van de patiënt is hiervoor belangrijk, blijkt uit onderzoek. Laat je verder in deze nieuwsbespreking met huisartsen Marco Krukerink en Sjoerd Bruggink bijpraten over de gevolgen van de klimaatverandering en risico's die daardoor voor COPD-patiënten ontstaan, het juiste moment om antihypertensiva in te nemen en AI-interventies bij de glucosecontrole. We sluiten deze podcast af met de column 'AI: afnemend Intelligent' van Annet Sollie. Luister mee!

Am 19. November ist Welt-COPD-Tag. Übersetzt steht COPD für „chronisch obstruktive Lungenerkrankung“. Typische Symptome sind Atemnot und Husten mit Auswurf. Viele Betroffene ziehen sich wegen der Beschwerden immer mehr zurück, dabei muss das nicht sein: Heutzutage gibt es Behandlungsoptionen, mit denen ein aktives Leben möglich sein kann, auch bei schwerer COPD. Im Podcast spricht dazu der Lungenfacharzt Professor Timm Greulich.

In this episode, Dr. David Traster sits down with Dr. Michael Lebowitz, DC and Dr. Noah Lebowitz, DC of Supreme Nutrition Products to uncover what's really driving the chronic disease epidemic — and how herbal medicine + integrative strategies can help turn the tide.

Ever had a patient swear it's their lungs—but the problem's really their heart? In this episode, we dig into cardiac dyspnea, the kind of shortness of breath that starts in the left ventricle, not the bronchi. You'll learn how pressure backs up into the pulmonary circuit, why patients can't lie flat without gasping, and what separates heart failure breathlessness from COPD or asthma. Perfect for paramedics who want to sharpen their clinical instincts and catch the subtle signs before the monitor does.

Airsupra is a combination inhaler that contains albuterol and budesonide, approved for as-needed use in adults with asthma. It represents the first rescue inhaler to combine a short-acting beta-2 agonist (SABA) with an inhaled corticosteroid (ICS) in a single device. The albuterol component provides rapid bronchodilation by relaxing airway smooth muscle, while budesonide works to reduce airway inflammation and mucus production. This dual mechanism allows Airsupra to not only relieve acute bronchoconstriction but also address the underlying inflammatory process that contributes to asthma exacerbations. Clinically, Airsupra is indicated for as-needed treatment or prevention of bronchoconstriction in adults with asthma, but it is not approved for COPD. The typical dosing is two inhalations as needed, with a maximum of six doses (12 inhalations) in a 24-hour period. The rationale for its use aligns with recent asthma guideline updates, which emphasize minimizing SABA-only use because it fails to address inflammation and may contribute to worse outcomes over time. Common adverse effects include tremor, nervousness, tachycardia, and hypokalemia from albuterol, as well as oral thrush and hoarseness from budesonide. Patients should rinse and spit after each use to reduce the risk of oral candidiasis. Drug interactions can occur with non-selective beta-blockers, which may blunt albuterol's effects. CYP3A4 also plays a role in budesonide metabolism. Systemic absorption typically isn't too much of an issue with infrequent use.

Delve into proven caregiver tips and support for families dealing with elderly parents who live longer but face health challenges. In this episode, caregiving expert Pamela D. Wilson shares insights on family caregiving experiences as age-related debilities like heart disease, dementia, COPD, Parkinson's, arthritis and other conditions limit activities and affect quality of life.Learn about care solutions and strategies to support caregivers with elderly parents living too long as they navigate complex health issues and relationships, ensuring both caregivers and elderly parents find workable options for daily living and life enjoyment.To find show transcripts and links mentioned in Episode 230 and other The Caring Generation podcasts, click here to visit Pamela's website: https://pameladwilson.com/caregiver-radio-programs-the-caring-generation/If you enjoy this podcast, please follow, like, and add a comment on your favorite podcast app to grow the audience and extend support to podcast listeners seeking information about health, aging, legal, and financial matters related to caregiving.For more caregiving, aging, and elder care tips, visit Pamela's website at www.PamelaDWilson.comLearn about Pamela D Wilson, her professional background, and her experience: https://pameladwilson.com/pamela-d-wilson-story/Schedule a 1:1 elder care consultation by telephone or video call with Pamela. https://pameladwilson.com/elder-care-consultant-aging-parent-consultation-managing-senior-care-needs-meet-with-pamela-d-wilson/Sign up for Pamela's newsletter: https://pameladwilson.com/contact/Join Pamela's Online Caregiver Support Group on Facebook https://www.facebook.com/groups/thecaregivingtrapFollow Pamela on Social Media: Facebook: https://www.facebook.com/pameladwilsoncaregivingexpert/Linked In: https://www.linkedin.com/in/pameladwilsoncaregiverexpert/X: https://x.com/CaregivingSpeakPamela D Wilson | Caregiver, Elderly Care & Caregiving Expert provides caregiver tips, support for caregivers, and resources for aging and elder care. Caregiving and aging for parents doesn't have to be challenging with expert caregiver advice, solutions, and strategies based on Pamela's 25 years of experience in care management, dementia care, and as an expert witness. Visit Pamela's website www.PamelaDWilson.com to access online caregiver programs, advice and tips to support caregivers and aging adults.©2018, 2025 Pamela D Wilson. All Rights Reserved

Lung cancer is the leading cause of cancer death in the United States for both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. This is because the disease shows no symptoms until it has progressed to advanced stages when it is very difficult to treat. The good news is that advances in imaging have made it possible to detect lung cancer early on, when treatment can be highly successful.The Eisenhower Lung Cancer Screening Program evaluates current and former smokers to determine their risk for lung cancer and provides assessment and evaluation for persons at risk for lung cancer.

Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment. These infants are at high risk for BPD because of a low level of a protective protein that reduces inflammation and clears infections from their underdeveloped lungs. The drug's mechanism of action suggests it has potential for treating other inflammatory conditions such as asthma, COPD, and severe pneumonia. Marc explains, "We're focusing on developing drugs or interventions for severe respiratory conditions for prevention or treatment of severe respiratory conditions. And our first project is focusing on the respiratory condition that preterm neonates have, which is called bronchopulmonary dysplasia, and cannot be treated or prevented yet. It's a very severe condition. And that really triggered my interest in getting engaged because it's going to be a paradigm shift if we manage to bring this drug to market." "The protein that we're developing is an endogenous protein that we all have. In the past years or decade, it has been discovered that this protein has a very essential function in fighting inflammation and infection on a daily basis. Now, there are certain conditions or instances where the protein is low-functioning. For instance, in preterm-born babies, but also in adults with severe respiratory inflammation, with pneumonias, with asthma, or COPD. In all those cases where protein is low, those are the instances where you actually need it most. So, replacing it in those instances is a kind of logical rationale for the concept for the treatment that we're developing." #AirwayTherapeutics #BPD #InflammatoryDiseases #Zelpultidealfa #PrematureBabies #PretermBabies airwaytherapeutics.com Download the transcript here  

Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment. These infants are at high risk for BPD because of a low level of a protective protein that reduces inflammation and clears infections from their underdeveloped lungs. The drug's mechanism of action suggests it has potential for treating other inflammatory conditions such as asthma, COPD, and severe pneumonia. Marc explains, "We're focusing on developing drugs or interventions for severe respiratory conditions for prevention or treatment of severe respiratory conditions. And our first project is focusing on the respiratory condition that preterm neonates have, which is called bronchopulmonary dysplasia, and cannot be treated or prevented yet. It's a very severe condition. And that really triggered my interest in getting engaged because it's going to be a paradigm shift if we manage to bring this drug to market." "The protein that we're developing is an endogenous protein that we all have. In the past years or decade, it has been discovered that this protein has a very essential function in fighting inflammation and infection on a daily basis. Now, there are certain conditions or instances where the protein is low-functioning. For instance, in preterm-born babies, but also in adults with severe respiratory inflammation, with pneumonias, with asthma, or COPD. In all those cases where protein is low, those are the instances where you actually need it most. So, replacing it in those instances is a kind of logical rationale for the concept for the treatment that we're developing." #AirwayTherapeutics #BPD #InflammatoryDiseases #Zelpultidealfa #PrematureBabies #PretermBabies airwaytherapeutics.com Listen to the podcast here  

In this episode of EMSconnect On Shift, Quinn dives deep into one of the most common and critical calls in prehospital care: respiratory emergencies. From asthma and COPD to CHF and pneumonia, Quinn breaks down the “Big 4” respiratory issues every EMS provider encounters and explores how to assess, treat, and manage these patients at the BLS level.Join us as we review key anatomy and physiology, discuss how to recognize respiratory distress before it becomes failure or arrest, and walk through scenario-based learning that challenges your clinical thinking. Whether it's setting up oxygen delivery systems, assisting with MDIs, or knowing when to call for ALS, this episode reinforces the importance of calm, calculated care when every breath counts.

The real beauty of inhalers is how they get these medications into your lungs. They work by suspending, or aerosolizing, medications into the air to be easily inhaled. Each type of inhaler does this in a slightly different way.吸入器真正的妙处在于，它能将药物高效地送入肺部。它的原理是将药物悬浮在空气中，或将其雾化成可吸入的微粒。而不同类型的吸入器实现这一过程的方式略有不同。Dry powder inhalers require a person to breathe in to aerosolize a powder medication.干粉吸入器需要使用者主动吸气，使粉末状药物被雾化并吸入肺部。Nebulizers, on the other hand, use either ultrasonic vibrations or compressed air to turn liquid medication into a mist.雾化器则利用超声波震动或压缩空气，将液态药物转化成细微的雾状颗粒。The pressurized metered-dose inhaler works a lot like hairspray. This medicine is dissolved in a fluid called a propellant, and it's under high pressure. This causes the fluid and medication mixture to shoot out in a fast-moving mist.加压定量吸入器（MDI）的工作方式与喷发胶非常相似。药物被溶解在一种称为推进剂的液体中，并处于高压状态。当按下装置时，药液与药物的混合物会以高速喷出，形成可吸入的雾气。But this mist can sometimes be hard to coordinate with breathing. So there's one more device, called a soft mist inhaler, that administers doses at lower speeds, without the use of a propellant.不过，这种喷雾有时需要与呼吸动作配合，操作并不总是容易。因此，又出现了一种称为“软雾吸入器”的装置，它不使用推进剂，而是以较低速度释放药物，使吸入更加平稳自然。Asthma and COPD each affects hundreds of millions of people worldwide each year. But thanks to inhalers, what once kept Proust confined to a cork-lined room, can now be treated in a few short puffs.哮喘和COPD每年都影响着全球数以亿计的人口。但多亏了吸入器，这种曾让普鲁斯特困于软木包裹房间、饱受折磨的疾病，如今只需几次轻轻吸入，就能得到有效控制。

Some stories are spoken. Others are lived so powerfully they outshine words. Karen Wilson joins us to share how a 17-year caregiving journey with her mother—through cancer, stroke, COPD, and chronic pain—became a living curriculum for resilience, presence, and protective love. When a stroke silenced her mother's speech, gestures and energy did the talking, teaching Karen to pour hope, choose her words with care, and treat gratitude as a daily state, not a polite reaction.We go deep on the mindset that sustains caregivers and anyone navigating long seasons of stress: how to make a life while making a living, why productivity can't replace purpose, and the role of consistent, simple wellness habits that actually stick. Karen opens her toolkit for advocacy inside hospitals and rehabs—health care proxies, durable power of attorney, reading treatment plans, and partnering with social workers—so you can push for better outcomes without burning bridges. If you've ever felt dismissed by “baseline” talk or boxed in by algorithms, this conversation offers language and strategy to stay strong and collaborative.Journaling threads it all together. Karen shares how themed journaling—anchored by words like Enough or Not Yet—helped her step back from crisis, process emotion, and return to presence. It's a practical, accessible way to manage caregiver burnout, reduce anxiety, and reclaim clarity. Along the way we reflect on loss, legacy, and the seeds mothers plant that keep blooming long after they're gone. Expect tangible tools, honest encouragement, and a gentle push to redefine success around love, laughter, and learning.If you're a caregiver, midlife listener, or anyone rebuilding after hardship, this one is for you. Tap play, share it with someone who needs strength today, and if it resonates, subscribe and leave a review so more people can find these conversations.Websitehttps://www.bykarenwilson.com/ -We hope you have enjoyed this episode. Please like, comment, subscribe, and share the podcast.To find out more about Lynnis and what is going on in the V.I.B.E. Living World please go to https://link.tr.ee/LynnisJoin the V.I.B.E. Wellness Woman Network, where active participation fuels the collective journey toward health and vitality. Subscribe, engage, and embark on this adventure toward proactive well-being together. Go to https://www.vibewellnesswomannetwork.com to join. We have wonderful events, courses, challenges, guides, blogs and more all designed for the midlife woman who wants to keep her V.I.B.E. and remain Vibrant, Intuitive, Beautiful, and Empowered after 40+.

Please visit answersincme.com/860/MED-RESP-03268-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a family medicine physician and a pulmonologist discuss strategies for optimizing chronic obstructive pulmonary disease (COPD) detection and management in primary care. Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations on the management of COPD; Identify the impact of approved follow-up pharmacotherapies in the treatment of COPD; and Determine personalized strategies to incorporate follow-up pharmacotherapies into clinical practice for COPD.

Please visit answersincme.com/860/MED-RESP-03268-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a family medicine physician and a pulmonologist discuss strategies for optimizing chronic obstructive pulmonary disease (COPD) detection and management in primary care. Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations on the management of COPD; Identify the impact of approved follow-up pharmacotherapies in the treatment of COPD; and Determine personalized strategies to incorporate follow-up pharmacotherapies into clinical practice for COPD.

In chronic bronchitis, the airway's lining is inflamed and produces more mucus to trap incoming smoke or dust particles. And the little hairs lining the airways that normally help push the mucus out are often damaged, so the mucus gets stuck. During a COPD attack, rescue inhalers open the airways, just as they do for asthma.在慢性支气管炎中，气道的内壁会发炎，并分泌出更多的黏液来捕捉进入的烟雾或灰尘颗粒。而那些原本排列在气道上的微小毛发（纤毛），通常负责将黏液向外排出，却常常受到损伤，导致黏液堆积无法排出。当COPD（慢阻肺）发作时，急救型吸入器可以像治疗哮喘一样，帮助打开气道。Preventative inhalers are used daily to stop asthma and COPD symptoms before they even start. They often contain both a corticosteroid, which reduces inflammation, and a long-acting bronchodilator.预防型吸入器则是每天使用，用来在哮喘或COPD症状出现之前就加以控制。它们通常同时含有糖皮质激素（可减少炎症）和长效支气管扩张剂。In fact, one class of bronchodilators for patients with COPD is related to the compounds in thorn apples. These drugs block signals from the nerves that tell the airway muscles to contract. Those same nerve signals are thought to be responsible for increasing mucus in the lungs, so these drugs may help clear the airways as well.事实上，用于治疗COPD患者的一类支气管扩张剂，其化学成分与曼陀罗中的化合物有关。这类药物通过阻断神经向气道肌肉发出的收缩信号来起作用。而这些神经信号也被认为会促进肺部黏液的增加，因此这种药物可能还能帮助清除气道。

So how do they work? When you take a breath, air travels through your lungs using tubes called airways, or bronchi. The airways funnel to sacs, called alveoli, where your red blood cells absorb all the oxygen your body needs.那么，它们是如何起作用的呢？当你吸气时，空气通过称为气道或支气管的管道进入肺部。气道最终通向被称为肺泡的气囊，红血球就在这里吸收身体所需的全部氧气。But if you have asthma, the muscles around your airways may tighten, the lining of your airways may get inflamed, and your lungs may make too much of the mucus they use to trap dust and germs. Essentially, this clogs the pipes and makes it difficult to exhale.但如果你患有哮喘，气道周围的肌肉可能会收缩，气道内壁可能发炎，而肺部可能会产生过多的黏液——这种黏液原本用于捕捉灰尘和病菌。结果就像管道被堵住一样，使呼气变得困难。Rescue inhalers deliver a medication called a bronchodilator that quickly relaxes these muscles, making it easier to breathe. These bronchodilators are short acting, lasting around four hours.急救型吸入器会输送一种名为“支气管扩张剂”的药物，它能迅速放松这些肌肉，使呼吸变得顺畅。这类支气管扩张剂属于短效药物，作用时间大约为四小时。Rescue inhalers can be used for COPD, too. COPD is a catch-all term to describe the most common breathing conditions, like emphysema and chronic bronchitis, which people often have at the same time.急救型吸入器同样可以用于治疗慢性阻塞性肺病（COPD）。COPD 是一个总称，用来描述最常见的呼吸系统疾病，如肺气肿和慢性支气管炎，这两种疾病往往会同时出现。In emphysema, repeated exposure to smoke or irritating particles breaks the inner walls of the alveoli. Because there's less surface area for blood and oxygen to interact, less oxygen makes its way to your bloodstream, causing you to constantly feel out of breath.在肺气肿中，长期接触烟雾或刺激性颗粒会破坏肺泡的内壁。由于血液与氧气交换的表面积减少，进入血液的氧气也随之减少，因此患者会持续感到呼吸困难。

In this compelling episode, we sit down with Mohamad Saad, MD, MBA, CPE, an internal medicine physician, healthcare leader, and certified coach, to explore solutions for two of healthcare's most pressing challenges: workforce disengagement and physician burnout. With 70% of employees disengaged and burnout at crisis levels, Saad presents a data-driven approach to organizational alignment and coaching that can revolutionize healthcare leadership. Why it matters: Burnout and disengagement don't just affect morale — they impact outcomes. Engaged employees are 1.5x more productive, and inspired employees are 2.25x more productive. Saad's alignment framework connects organizational vision and goals to frontline work, creating purpose-driven teams that thrive. Key Insights: - The alignment triangle: How cascading vision → mission → goals → SMART objectives → projects, drives measurable improvements. - Three types of alignment: Vertical (vision to frontline), horizontal (cross-departmental), and diagonal (interdisciplinary connections). - Coaching vs. directing: Why empathetic listening and powerful questions unlock potential better than traditional leadership. - AI's role in healthcare: How artificial intelligence will amplify emotionally intelligent physicians while challenging those still developing intrinsic skills. Real-world results: As a residency program director, Saad aligned resident quality improvement projects with hospital operational goals, significantly reducing length-of-stay for heart failure, pneumonia, and COPD patients. Bottom line: Healthcare leaders need tools like organizational alignment and coaching to combat burnout, inspire teams, and prepare for the future. Saad's insights offer actionable strategies for creating engaged, purpose-driven organizations. Connect with Mohamad Saad, MD, MBA, CPE, http://linkedin.com/in/mohamad-s-saad-md-mba-cpe-dipablm-icf-coach-b80533371 Learn more about the American Association for Physician Leadership.

Early 20th century writer, Marcel Proust, finished his magnum opus “In Search of Lost Time” from bed— in a cork-lined room to keep allergens out. Proust suffered from severe asthma. At the time, there weren't great treatments. When breathlessness set in, he'd burn powders that filled the space with smoke and fumes. Or, for a quick fix, he'd smoke a doctor-recommended anti-asthma cigarette. These powders and cigarettes commonly contained thorn apple, which can open your airways. However, both were clearly terrible ideas. Smoking and fumes bring damaging, carcinogenic toxins into your lungs.二十世纪初的作家马塞尔·普鲁斯特，在床上完成了他的鸿篇巨著《追忆似水年华》——他住在一个用软木塞包裹的房间里，以隔绝过敏原。普鲁斯特患有严重的哮喘，而当时并没有有效的治疗方法。当他呼吸困难时，会燃烧一些粉末，使房间充满烟雾和气味；或者，为了快速缓解，他会抽医生推荐的“抗哮喘香烟”。这些粉末和香烟通常含有曼陀罗成分，可以帮助打开气道。然而，这两种做法显然都是糟糕的主意——吸入烟雾会把有害的致癌毒素带入肺部。Thankfully, today we have inhalers— simple but powerful devices that deliver lung medications straight to the source and without the nasty side effects of smoke inhalation.幸运的是，如今我们有了吸入器——这种简单而强大的装置能将药物直接输送到肺部病灶处，而不会产生吸入烟雾带来的副作用。Inhalers are mainly used to treat two conditions: asthma and chronic obstructive pulmonary disease, or COPD. And there are two main types: preventative inhalers and rescue inhalers. Preventative inhalers can be used every day to control symptoms. There are also rescue inhalers, which are great in an emergency, but using them regularly can be dangerous.吸入器主要用于治疗两种疾病：哮喘和慢性阻塞性肺病（COPD）。吸入器分为两大类：预防型吸入器和急救型吸入器。预防型吸入器可以每天使用，以控制症状；而急救型吸入器在紧急情况下非常有用，但若经常依赖使用则可能带来危险。

Right Thinking with Steve Coplon.This week's show is called "Row, Row, Row Your Boat." Tune in and hear Steve share valuable insights into one of the strongest core parts of his character and personality – Perseverance. Believing in yourself and knowing that you have reasons to not give up, will motivate you toward success. Stay tuned in till the end of this powerful show and learn what motivates Steve.In this episode of Right Thinking, I delve into perseverance through personal stories, particularly my journey battling COPD and the lessons learned from cardio rehabilitation. Titled "Row, Row, Row Your Boat," I highlight the importance of steady progress and community support in overcoming challenges.Drawing parallels between rowing and life, I discuss resilience and the significance of acceptance in the face of setbacks. Using quotes from influential figures, I encourage listeners to reflect on their own journeys and find motivation in family and community. The episode emphasizes that persistent effort and a positive mindset are essential for navigating life's obstacles.https://www.talknetworkradio.com/hosts/right-thinking

Episode 2708 - Vinnie Tortorich and Chris Shaffer welcome call-in guests to discuss motivation sparked by one foot in the grave, and pushback from family. https://vinnietortorich.com/2025/10/one-foot-in-the-grave-episode-2708 PLEASE SUPPORT OUR SPONSORS   YOU CAN WATCH THIS EPISODE ON YOUTUBE - One Foot In The Grave Social media concerns. (2:00) Vinnie had an experience over X years ago regarding American Girl dolls. (4:00) There was a miscommunication, and he had to stay up all night to correct the mistake. Vinnie had only suggested making a fitness-themed doll. Eric is the first guest caller. (18:00) He's lost some weight with NSNG® and has spine issues. Eric is looking forward to Vinnie's workout videos that will be released in the NSNG® VIP group. They discuss issues Eric has had dealing with cholesterol and his doctor. (30:00) The ratio between HDL and Triglycerides is a better indicator of heart health. Carbohydrates really don't help you build muscle; 5g of creatine is better. (43:00) Some sports or competitions can be fueled with a small sugar trickle because blood glycogen gets used up so quickly. Examples would be kickboxing or boxing. Family Pushback Scott is the next guest. He has lost 325 pounds after starting NSNG® after hearing Vinnie on Mike Rowe's podcast. Why does it take people to be told they have one foot in the grave before it sparks change? (48:00) Scott's wife has lost over 100 pounds, and his son has lost 90 pounds! Scott has reversed COPD and congestive heart failure symptoms. (55:00) Hobbies are important to help your mind explore. (1:01:00) Scott has had family blowback about his new healthy lifestyle. A family member reported him to Adult Protective Services! (1:04:00) He had to go through three months of investigation. The accusation was abuse because of the change in eating and daily walks. Scott's wife has lowered her A1C and gotten off of insulin. (1:11:00) Vinnie shares a story about an NSNG® follower named Robert Stanton. (1:19:00) If you are interested in the NSNG® VIP group, it will be reopening soon. But you can get on the wait list - More News If you are interested in the NSNG® VIP group, it will be reopening soon. But you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it! Eat Happy Italian, Anna's next cookbook, is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.    PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: 

DMSO is an "umbrella remedy" capable of treating a wide range of challenging ailments due to its combination of therapeutic properties (e.g., reducing inflammation, improving circulation, and reviving dying cells). It also rapidly transports substances dissolved in it through the skin and throughout the body These benefits are also seen when DMSO is combined with a variety of natural therapies – in many cases, allowing the mixture to treat challenging conditions neither could treat alone DMSO is commonly combined with proven nutraceuticals, such as vitamins and antioxidants These combinations effectively treat a myriad of diseases, including skin cancer, prostate enlargement, cataracts, CRPS, fatigue, lost smell or hearing, osteoarthritis, COPD, and tinnitus This article will review the basics of botanical DMSO combinations, the literature supporting it, and show how these mixtures can be used to treat many additional challenging medical conditions

Luca is a 68 year old male with moderate COPD who is referred for physical therapy to improve exercise tolerance. He reports dyspnea with minimal exertion and has a 6-minute walk test distance of 250 meters. His resting oxygen saturation is 92% on room air. Which of the following is the MOST appropriate initial exercise approach?A) Interval training with short work and rest periods at moderate intensityB) Continuous training at 75% of peak work rate to build enduranceC) Resisted walking with a weighted vest to strengthen lower extremitiesD) Breathing retraining combined with unsupported upper extremity exercisesJoin the FREE Facebook Group: www.nptegroup.com

GOLD Updates, Novel Treatments, and Managing Comorbidities in COPD Care Level up your COPD care with practical, evidence-based strategies. Learn how to confirm airflow obstruction with spirometry (and use LLN/Z-scores thoughtfully), stage patients with the A/B/E framework, and build treatment around long-acting bronchodilation—adding ICS selectively based on exacerbations and eosinophils. We'll highlight the nonpharmacologic moves that change outcomes (smoking cessation, vaccination, pulmonary rehab, oxygen when indicated), when to reach for add-ons (azithromycin, roflumilast), how to approach chronic hypercapnia with home NIV, and what's new (hello, ensifentrine). Pulmonologist and longtime Curbsiders member Dr. Cyrus Askin (@Askins_Razor ) returns to share real-world pearls for diagnosing, treating, and managing comorbidities in COPD. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case 1 Diagnostic Workup Understanding the Ratio, LLN/Z-Scores, and Equity Symptom abd Risk Staging (A/B/E) Case 2 Foundational Care  Initial Inhaler Strategy  Progression & Hypercapnia: NIV & Adherence Counseling Add-On Pharmacologic Options for Frequent Exacerbators What's New and Emerging Comorbidities and When to Refer  Take-Home Points Recap Plugs, CME, and Credits Credits Written and produced by Paul Wurtz MD. Show notes, cover art, and infographic also created by Paul Wurtz MD. Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Cyrus Askin MD   Sponsor - Freed Use code: CURB50 to get $50 off your first month when you subscribe at freed.ai Sponsor - Grammarly Sign up for FREE and experience how Grammarly can elevate your professional writing from start to finish. Visit Grammarly.com/podcast Sponsor -Locumstory Learn about locums and get insights from real-life physicians, PAs and NPs at Locumstory.com

Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

CHEST October 2025, Volume 168, Issue 4  CHEST® journal's Editor in Chief Peter Mazzone, MD, MPH, FCCP, highlights key research published in the journal CHEST October 2025 issue, including an exploration of the association of physical frailty with incidence and life expectancy of COPD, an investigation of the health and utilization burden of OSA among US active-duty military personnel, and more.     Moderator:    Peter Mazzone, MD, MPH, FCCP

Federal cuts to the the NIH and other key research organizations have left both researchers and patients paying the price. Erika Moseson, MD, of the Air Health Our Heath podcast, talks with Mary Rice, MD, MPH, of Harvard T.H. Chan School of Public Health, about how these cuts have not only hurt her research on helping patients with respiratory illnesses, but the larger impact they have on science now and for future generations. Read the article in STAT News about Dr. Rice's study: https://www.statnews.com/2025/08/08/trump-cuts-include-cost-saving-research/ 

In Nederland kampen ruim 1,2 miljoen mensen met een chronische longaandoening, zoals COPD, astma of longfibrose. Voor hen kan een simpele verkoudheid of griep al uitmonden in een ernstige longaanval, met wekenlang herstel of een ziekenhuisopname tot gevolg. Hoe kunnen we deze groeiende groep patiënten beter beschermen en hun kwaliteit van leven verbeteren? In deze aflevering van BNR Beter spreekt Nina van den Dungen met twee longartsen die elk vanuit hun expertise naar oplossingen zoeken:

When a trusted doctor changed his medication without consulting his psychiatrist, what started as a routine visit spiraled into a night of crisis. After three weeks of worsening mood and breathing problems, her husband — already battling long-term depression and COPD — texted that it was “over.” She raced home, instinct telling her where he would be. What followed was part survival story, part mystery: she pulled the garage door open, grabbed the keys from the ignition and called 911. He was rushed to the hospital and later admitted to a psychiatric facility. Doctors said he should not have survived as long as he did, yet he pulled through. But the story doesn't end with medicine and ER lights. On the drive home from the hospital, she looked into her rearview mirror and saw a face appear — her father-in-law, the very man who had taken his own life the same way years earlier. He told her, without words, that he'd been with his son in the garage and saved him that day. Her husband didn't believe at first. But between the inexplicable survival and that rearview encounter, the family was left asking: coincidence, guardian spirit, or something else? #MiracleSurvival #GuardianSpirit #MentalHealth #DepressionRecovery #Paranormal #TrueGhostStory #RearviewApparition #MedicalMistake #NearDeath #RealGhostStoriesOnline Love real ghost stories? Don't just listen—join us on YouTube and be part of the largest community of real paranormal encounters anywhere. Subscribe now and never miss a chilling new story:

Get My Book On Amazon: https://a.co/d/avbaV48DownloadThe Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/1 On 1 Coaching Application: https://hunterwilliamscoaching.carrd.co/Book A Call With Me: https://hunterwilliamscall.carrd.co/Supplement Sources: https://hunterwilliamssupplements.carrd.co/Amazon Storefront: https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DYSocials:Instagram: https://www.instagram.com/hunterwilliamscoaching/Podcast: https://hunterwilliamspodcast.buzzsprout.com/Video Topic Request: https://hunterwilliamsvideotopic.carrd.co/In this 2025 refresh I walk through why GHK-Cu remains one of the most versatile, well-tolerated peptides for systemic repair and cosmetic wins. I cover mechanisms (copper delivery + gene modulation), data across tissues (skin, bone, liver, lung, gut, nerves), and performance/brain angles (sleep loss resilience, anxiolysis, analgesia). I also talk realistic use cases, stacking concepts, and where the research is heading—plus how I'm rebuilding after my original channel was deleted. If this helped, drop a comment and make sure you're on my email list so we can stay connected no matter what platforms do next.0:00 - Intro, channel update & why I'm revisiting GHK-Cu3:09 - What is GHK-Cu? Discovery, decline with age & why it still matters4:46 - Core mechanisms: copper delivery + gene-expression “reset”9:50 - Wound healing fundamentals (closure, granulation, angiogenesis)11:06 - Systemic healing even under steroids (cortisone models)13:00 - Organ regeneration: liver “youth,” COPD gene signature, gut lining14:18 - Ulcerative colitis 2025 study: cytokines down, barrier up17:10 - Skin rejuvenation: collagen, firmness, pigmentation18:20 - Hair growth: anagen extension, minoxidil-level results22:08 - Practical stacks, safety notes & key takeaways

Chronic obstructive pulmonary disease (COPD) is climbing the priority list for health systems, driven by rising prevalence, an aging population and new therapeutic innovations. In this episode, Sg2 expert Emily Fitt joins host Trevor DaRin to explore why COPD demands renewed focus, highlight successful care models—from academic medical centers to rural programs—and discuss the role of specialty pharmacy, telemedicine, and care redesign. Listeners will gain insight into how proactive strategies can improve outcomes, reduce hospitalizations and create real value for patients and providers alike.   Sg2 Perspectives Listener Feedback Survey: We would love to hear from you - Please click here   We are always excited to get ideas and feedback from our listeners. You can reach us at sg2perspectives@sg2.com, or visit the Sg2 company page on LinkedIn.  

Please visit answersincme.com/XVH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the role of biologic therapy in patients with eosinophilic chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify patients with unmet therapeutic needs despite guideline-recommended management of chronic obstructive pulmonary disease (COPD); Review the clinical rationale for approved and emerging biologics targeting type 2 inflammation in the treatment of eosinophilic COPD; and Assess strategies to incorporate biologics targeting type 2 inflammation into clinical practice for COPD, as they become available.

COPD, Asthma, Allergien – von pneumologischen Erkrankungen Betroffene wird es in Zukunft noch stärker treffen. Worauf wir uns durch die geänderten klimatischen Bedingungen in den nächsten Jahren einstellen müssen und wie sich die Beschwerden lindern lassen, darüber haben wir mit Dr. Christian Grah, einem der Autoren des Positionspapiers "Pneumologie im Klimawandel", gesprochen.

Audio roundup of selected biopharma industry content from Scrip over the business week ended September 19, 2025. In this episode: GSK announces US investments during Trump's UK visit; Lilly thinks twice about UK lab investment; analyzing the rise in China R&D and deals; Regeneron CEO on his company's ignored blockbusters; and AstraZeneca's COPD trial failure. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-D4VJFG2XNJGAJEFGSXNEQUA3BU/ Sign up for China R&D webinar: https://www.citeline.com/en/events/china-transforming-pharma This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

In this episode of the Smarter Not Harder Podcast, Dr. Vivek Lal joins Dr. Scott Sherr for a groundbreaking and eye-opening conversation about the gut-lung axis — the overlooked connection between your microbiome and your ability to breathe, perform, and recover. From inhaled probiotics to AI‑driven lung therapy, this episode bridges clinical science and next‑gen wellness in a way you've never heard before. Join us as we delve into: How gut bacteria directly influence lung inflammation, asthma, and COPD Why your lungs aren't sterile — and what lives in them might save your life The rise of inhaled postbiotics and what “air as medicine” really means Cutting-edge lung science: AI, organoids, omics, and future therapies This episode is for you if: You've never heard of the gut-lung axis but want to breathe, sleep, and recover better You or someone you love has asthma, COPD, or unexplained breathing issues You're fascinated by how microbiomes affect health far beyond the gut You want smarter, not harder, ways to optimize lung health and longevity You can also find this episode on…  YouTube: https://youtu.be/PZZw8ulAHiM  Find more from Dr. C. Vivek Lal, MD, FAAP: Resbiotic Nutrition: https://resbiotic.com/ LinkedIn: https://linkedin.com/in/c-vivek-lal-md-faap-20183913 Instagram: https://instagram.com/dr.viveklal/ Find more from Smarter Not Harder: Website: https://troscriptions.com/pages/podcast Instagram: https://instagram.com/troscriptions/ HOMeHOPe Symposium: https://homehope.org/homehope-symposium Get 10% Off your purchase of the Gut Lung Axis Module by using PODCAST10 at https://www.homehope.org Get 10% Off your Troscriptions order with code POD10 at https://www.troscriptions.com

Gina Hoots joins Cathy to explore where respiratory therapy meets health coaching, especially for people living with chronic lung conditions such as COPD, asthma, bronchiectasis, and more. With over 30 years' experience in both clinical and community settings, Gina shares how she combines science and compassion in her work. We dive into practical breathing techniques, the importance of proper inhaler use, integrating nutrition and lifestyle, and coaching strategies that empower clients beyond traditional medicine. The episode also highlights Gina's work with BluZone.Health, her leadership in respiratory care, and how health coaches and respiratory therapists can collaborate to improve outcomes. Expect both deeply technical takeaways and inspiring mindset shifts. In this episode, you'll discover: How Gina's dual roles as a respiratory therapist and health coach allow her to bridge gaps in patient education, care, and quality of life. Specific breathing practices (nose inhalation, lip‑pursed exhalation, huff coughs, etc.) that help reduce breathlessness, move mucus, and calm anxiety. How to assess if someone is on the “right” inhaler(s) vs. just using rescue inhalers, and what coaches should know about various inhaler classes. Ways health coaches can help clients being proactive in doctor visits—preparing questions, reviewing action plans, and improving collaboration. The role of nutrition, exercise, and reducing environmental/inflammatory exposures in lung health, not just “medication + oxygen.” The gaps in care Gina sees—where patients often don't get enough time, education, or follow‑up—and how health coaches and RTs can fill those gaps. Practical mindset shifts: turning directives into partnership, helping clients find personal “why,” and using breathing as a tool for anxiety and agency. Memorable Quotes: “If you have breathing problems, you're going to get an inhaler. Nobody tests for the breathing like they should.” “Many people think just with breathing problems, oxygen is the answer … But exercise can help that. Breath work … all of that really helps.” “The numbers don't really matter, but just the mindful breathing that you can control your breath.” Bio: Gina Hoots is a nationally recognized respiratory therapist and health coach with over 30 years of clinical and community experience, specializing in chronic lung conditions. As a Health Coach for BluZone.Health, Gina helps individuals live well with COPD, asthma, and other chronic respiratory illnesses through education, behavior change, and lifestyle optimization. She is the co‑creator and co‑host of The Cozy Lung Lounge Podcast, a compassionate, patient‑centered show offering real‑talk and resources for people with chronic lung disease and their caregivers. Whether it's unpacking new science or exploring the emotional side of illness, Gina's podcast makes space for the full experience of breathing and healing. Gina currently serves as the President of the Illinois Society for Respiratory Care, where she champions professional excellence and advocacy for the respiratory therapy field. She is also a COPD Foundation Captain, leading awareness efforts and community‑based support across Central and Southern Illinois. Rooted in both science and spirit, Gina is a proud member of the American Association for Respiratory Care and the Holistic Nurses Association, weaving a whole‑person approach into everything she does. From pulmonary testing labs to health coaching sessions, her mission is simple: to help people breathe easier and live more fully. Connect with Gina and explore her programs at hootenannyjoy.com. Mentioned in This Episode: Hootenanny Joy Recharge Your Day The Cozy Lung Lounge Podcast BluZone.Health Illinois Society for Respiratory Care COPD Foundation Asman Allergy Network Bronchiectasis & NTM Organization Links to Resources: Health Coach Group Website: thehealthcoachgroup.com Special Offer: Use code HCC50 to save $50 on the Health Coach Group website Leave a Review: If you enjoyed the podcast, please consider leaving a five-star rating or review on Apple Podcasts.

Novel Imaging Techniques and Phenotypes in Asthma and COPD

Revefenacin (brand name Yupelri) is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by blocking muscarinic receptors, particularly the M3 subtype, in airway smooth muscle. This antagonism reduces cholinergic bronchoconstriction and leads to sustained bronchodilation. Unlike short-acting anticholinergics such as ipratropium, revefenacin provides 24-hour bronchodilation with once-daily dosing. One of the distinguishing features of revefenacin is that it is the first nebulized LAMA approved for COPD maintenance therapy. Many patients with advanced COPD, physical limitations, or difficulty using handheld inhalers benefit from a nebulized formulation, as it allows medication delivery without requiring hand-breath coordination or a forceful inhalation. This makes it a useful option for patients with poor inhaler technique or those transitioning from hospital care. Pharmacokinetically, revefenacin is delivered via nebulization, with peak effects typically observed within a couple of hours. Importantly, systemic absorption is relatively low, but elderly patients or those with hepatic impairment may be more susceptible to anticholinergic side effects. Clinically, revefenacin improves lung function, reduces COPD symptoms, and can decrease exacerbation frequency. Common adverse effects include cough, dry mouth, constipation, and urinary retention. Caution is advised in patients with narrow-angle glaucoma or prostatic hyperplasia due to its antimuscarinic properties. Revefenacin is not intended for acute bronchospasm or rescue therapy—it is strictly for long-term, once-daily maintenance.

On today's Good Day Health Show - ON DEMAND…Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health.First up, Doug and Dr. Ken discuss the biggest news stories in the medical world, starting with a focus on new findings on COVID-19 silently accelerating the aging of arteries with a sharp in crease for women, updated guidance from the FDA on updated COVID-19 vaccines, and why the CDC and FDA aren't seeing eye-to-eye.Then, a discussion on Omega-3s and the difference between Omega-3, Omega-6 and Omega-9.Next up, the latest AI algorithm in a trial helps match potential volunteers to relevant medical trials in an effort to speed up the enrollment process and accelerate the pace of research to make it easier and faster to match patients with the proper studies.Doug gives an update on his hearing troubles with his left ear after having a lady bug stuck in his ear. This revelation leads to a discussion on hearing aids and the connection between hearing problems and early dementia/Alzheimer's.Then, a new non-opioid pain killer that offers relief without the risk of addiction.Lastly, Doug and Dr. Ken address listener questions, including the link between passive smoking and the risk of getting COPD. Are you ready for this? It appears that a father's exposure to passive smoking as a child may impair the lifelong lung function of this children, increasing their risk of developing COPD. Let that sink in.Another question addressed — “What happens if we skip breakfast later in life?” Turns out, this could lead to a higher likelihood of developing osteoporosis. Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Host Dr. Riley Kirk is joined by Dr. Janice Makela, MD for part one of a two part episode; the conversation was so interesting they couldn't cut it short! They discuss the evolving landscape of cannabis medicine, particularly for the geriatric population. She emphasizes the importance of education for both patients and physicians, addressing common misconceptions and the need for responsible dosing. The discussion covers various consumption methods, including edibles and tinctures, and highlights the potential benefits and risks associated with cannabis use in older adults. Dr. Makela also shares insights on the importance of safe and legal access to cannabis products. The discussion delves into the risks associated with smoking, including bronchitis and COPD, and highlights the benefits of using vaporizers over traditional smoking methods. The speakers also discuss the efficacy of cannabis topicals for pain relief and their role in wound care, and the importance of considering drug interactions. The speakers advocate for a cautious approach to cannabis use, especially among older adults and those with existing health conditions. Please consult your physician or health care team for questions that relate specifically to your health. Find out more about Dr. Janice Makela, MD: https://www.janicemakelamd.com/ Want Exclusive Content and ad-free episodes? Join the Bioactive Patreon community for as little as $1/month to ask guests your burning questions, access exclusive content, and connect with Dr. Kirk one-on-one.⁠⁠⁠⁠⁠⁠⁠ www.Patreon.com/Cannabichem⁠⁠⁠⁠⁠⁠⁠

Fielding West has been a fixture of the Las Vegas comedy scene for over 50 years. But time has taken its toll and he now suffers from Emphysema, a form of COPD. But despite having to be strapped with an oxygen tank 24/7, Fielding has found a way to keep on his path of teaching people how to speak better on stage plus being part of the “Lance Burton and Friends” tour. He has even incorporated a way to make his audiences laugh with him at his malady. View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize Fielding is like the Everyready bunny that just keeps going, and going, and going. He continues to make people laugh with his antics on stage and has even just been recognized by the International Magicians Society (IMS) with yet another Merlin Award. This episode was recorded in May 2025 and long before he knew he was going to be receiving this award. Download this podcast in an MP3 file by Clicking Here and then right click to save the file. You can also subscribe to the RSS feed by Clicking Here. You can download or listen to the podcast through Pandora and SiriusXM (formerly Stitcher) by Clicking Here or through FeedPress by Clicking Here or through Tunein.com by Clicking Here or through iHeart Radio by Clicking Here. If you have a Spotify account, then you can also hear us through that app, too. You can also listen through your Amazon Alexa and Google Home devices. Remember, you can download it through the iTunes store, too. See the preview page by Clicking Here. Enter for a Chance to Win a Copy of Castle Notes: Thoughts on the "Why" as well as the "How" by Steve Friedberg Enter with your name and email address. Hard copies will be shipped within the U.S. compliments of the author. PDF copies will go to those winners who reside outside the U.S. First Name Last Name Email Address Enter Today We respect your privacy. Your email will only be shared with the author. Thank you for entering the contest. If your name is randomly selected, then an email will be sent to you requesting your physical address where the book should be sent. Good luck!

We break down pneumothorax: risks, diagnosis, and management pearls. Hosts: Christopher Pham, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Pneumothorax.mp3 Download Leave a Comment Tags: Chest Trauma, Pulmonary, Trauma Show Notes Risk Factors for Pneumothorax Secondary pneumothorax Trauma: rib fractures, blunt chest trauma (as in the case). Iatrogenic: central line placement, thoracentesis, pleural procedures. Primary spontaneous pneumothorax Young, tall, thin males (10–30 years). Connective tissue disorders: Marfan, Ehlers-Danlos. Underlying lung disease: COPD with bullae, interstitial lung disease, CF, TB, malignancy. Technically, anyone is at risk. Symptoms & Differential Diagnosis Typical PTX presentation: Dyspnea, chest pain, pleuritic discomfort. Exam clues: unilateral decreased breath sounds, focal tenderness/crepitus. Red flags (suggest tension PTX): JVD Tracheal deviation Hypotension, shock physiology Severe tachycardia, hypoxia Differential diagnoses: Pulmonary: asthma, COPD, pneumonia, pulmonary edema (SCAPE), ILD, infections. Cardiac: ACS, CHF, pericarditis. PE and other acute causes of dyspnea. Diagnostics Bloodwork: limited role, except type & screen if intervention likely. EKG: reasonable given chest pain/shortness of breath.

Mary Iannelli sits down with former TPJ alum, James Lynch to see what it's like to take on an iconic role off broadway and then take it on the road as part of a national touring company.Credits:Audio Engineer Gary GlorOne Heartbeat Away is provided to The Theater Project by Gail Lou References:Saw, The Musicalhttps://www.sawthemusical.com/Backstagehttps://www.backstage.com/Zicam Nasal Swabshttps://www.zicam.com/our-products/cold-shortening/nasal-swabsNeti PotA neti pot is a device used for nasal irrigation, typically to flush out mucus and allergens from the nasal passages. It's a teapot-like container with a long spout, allowing you to pour a saline solution into one nostril, which then flows out the other. This process helps relieve symptoms of allergies, colds, and sinus congestion.Portable NebulizerA portable nebulizer is a compact, handheld medical device that converts liquid medication into a fine mist for inhalation, making it convenient for on-the-go use or travel. It offers a discreet and quiet way to deliver medication directly to the lungs, which is helpful for individuals with respiratory conditions like asthma or chronic obstructive pulmonary disease (COPD).Vocal ResonanceVocal resonance is the process of amplifying and enriching the sound of your voice by using the resonating cavities in your head and throat. It's like an echo, where the sound waves bounce off reflective surfaces and enhance the sound's quality and projection. Think of it as the way your voice sounds full, rich, and carries well.

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠COPD Exacerbation⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Pulmonary section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Top 7 Underrated Supplements Top 7 Underrated Supplements. (1:11) #1 - Vitamin D. (50%) take 2000-4000iu. (2:01) #2 - Vitamin k2. (97%) 100micrograms a day. (8:48) #3 - NAC. 600-1800mgs a day. (11:52) #4 - Berberine. 500mgs 3x day w/food. (13:23) #5 - Glycine. Take before bed on an empty stomach. (15:34) #6 - Choline. 500-2000mgs a day. (17:04) #7 - Grape seed extract. 100-300mgs daily. (21:18) Related Links/Products Mentioned Visit MASSZYMES by biOptimizers for an exclusive offer for Mind Pump listeners! **Code MINDPUMP10 at checkout for 10% off any order. ** July Special: MAPS Split or Anabolic Metabolism Bundle 50% off! ** Code JULY50 at checkout ** Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis Efficacy of vitamin D supplementation in major depression: A meta-analysis of randomized controlled trials Impact of vitamin D supplementation on C-reactive protein; a systematic review and meta-analysis of randomized controlled trials 97% of Americans are Low In Vitamin K2 Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis Mind Pump #2060: Maximize Fat Loss With Continuous Glucose Monitors: Kara Collier Efficacy of Berberine in Patients with Type 2 Diabetes - PMC The Effects of Glycine on Subjective Daytime Performance in Partially Sleep-Restricted Healthy Volunteers 6 Warning Signs of Choline Deficiency You Must Watch For The impact of grape seed extract treatment on blood pressure changes Visit Legion Athletics for the exclusive offer for Mind Pump listeners! ** Code MINDPUMP for 20% off your first order (new customers) and double rewards points for existing customers. ** Mind Pump Podcast – YouTube Mind Pump Free Resources  

Story at-a-glance Chronic respiratory diseases remain profitable but poorly treated, subjecting patients to expensive healthcare, impaired stamina, and painful decline DMSO is an "umbrella remedy" treating diverse ailments through therapeutic properties including reducing inflammation, improving circulation, and reviving dying cells These properties uniquely address underlying causes of chronic respiratory diseases by reducing fibrosis and inflammation, restoring damaged organs, and improving circulation DMSO addresses respiratory infections through antimicrobial activity, reduced lung inflammation, and potentiation of antimicrobial therapies Extensive published data and user reports demonstrate DMSO's remarkable results for asthma, COPD, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and pneumonia, including cases in which transplant was no longer necessary due to significant organ recovery